A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 9,109 shares of RYTM stock, worth $446,796. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,109
Previous 9,118 0.1%
Holding current value
$446,796
Previous $395,000 5.32%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$35.41 - $44.37 $318 - $399
-9 Reduced 0.1%
9,109 $374,000
Q1 2024

Apr 25, 2024

SELL
$39.12 - $52.44 $2,464 - $3,303
-63 Reduced 0.69%
9,118 $395,000
Q4 2023

Jan 30, 2024

BUY
$21.39 - $49.64 $8,684 - $20,153
406 Added 4.63%
9,181 $422,000
Q3 2023

Oct 25, 2023

SELL
$15.81 - $27.8 $2,750 - $4,837
-174 Reduced 1.94%
8,775 $201,000
Q2 2023

Aug 07, 2023

SELL
$16.32 - $21.15 $2,594 - $3,362
-159 Reduced 1.75%
8,949 $147,000
Q1 2023

May 08, 2023

BUY
$16.88 - $34.24 $37,625 - $76,320
2,229 Added 32.4%
9,108 $162,000
Q4 2022

Feb 01, 2023

BUY
$22.21 - $30.25 $15,347 - $20,902
691 Added 11.17%
6,879 $200,000
Q3 2022

Nov 09, 2022

BUY
$4.3 - $30.85 $10,517 - $75,459
2,446 Added 65.37%
6,188 $152,000
Q1 2022

Apr 21, 2022

SELL
$6.13 - $12.24 $10,151 - $20,269
-1,656 Reduced 30.68%
3,742 $43,000
Q4 2021

Feb 01, 2022

SELL
$8.62 - $13.9 $1,491 - $2,404
-173 Reduced 3.11%
5,398 $54,000
Q2 2021

Jul 30, 2021

BUY
$18.52 - $22.55 $1,277 - $1,555
69 Added 1.25%
5,571 $109,000
Q1 2021

May 03, 2021

BUY
$20.25 - $39.49 $35,640 - $69,502
1,760 Added 47.03%
5,502 $117,000
Q2 2020

Jul 28, 2020

BUY
$14.41 - $25.35 $22,421 - $39,444
1,556 Added 71.18%
3,742 $83,000
Q4 2019

Jan 21, 2020

BUY
$19.53 - $25.5 $42,692 - $55,743
2,186 New
2,186 $50,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.73B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.